OSCR
Oscar Health, Inc.
OSCR has slightly lower modeled downside risk, despite its lower overall score.
ZETA
Zeta Global Holdings Corp.
ZETA has the edge over OSCR overall, supported by stronger modeled upside.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ZETA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Healthy |
ZETA's revenue, profitability, cash flow and balance sheet are all currently healthy.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
ZETA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 29x | $37.27 | — |
| Current | 248x | $37.27 | — |
| Cheap | N/A | N/A | N/A |
| Fair | N/A | N/A | N/A |
| Expensive | N/A | N/A | N/A |
Historical ranges are pointers, not guarantees.
ZETA has the edge over OSCR in the historical PE scenario, which offers more potential upside but is not a forecast.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
ZETA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for ZETA, with profitability improving. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
ZETA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.27 | +748% |
| Q3 2026 | $0.15 | +$0.23 |
| Q2 2026 | -$0.01 | +$0.14 |
| Q1 2026 | -$0.10 | +$0.15 |
| Q4 2025 | -$0.14 | +$0.24 |
| Q3 2025 | -$0.08 | +$0.61 |
| Q2 2025 | -$0.15 | +$0.72 |
| Q1 2025 | -$0.25 | +$0.80 |
| Q4 2024 | -$0.38 | +$0.82 |
ZETA has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over ZETA on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
ZETA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $492.7M | +46% |
| Q2 2026 | $442.8M | +44% |
| Q1 2026 | $396.3M | +50% |
| Q4 2025 | $394.6M | +25% |
| Q3 2025 | $337.2M | +26% |
| Q2 2025 | $308.4M | +35% |
| Q1 2025 | $264.4M | +36% |
| Q4 2024 | $314.7M | +50% |
ZETA's revenue has grown year over year every quarter since early 2021: $493M last quarter, up 46% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 9.3% | +6.7 points |
| Q2 2026 | 3.8% | +5.5 points |
| Q1 2026 | -4.8% | +1.3 points |
| Q4 2025 | 4.5% | +2.3 points |
| Q3 2025 | 2.6% | +7.2 points |
| Q2 2025 | -1.7% | +10 points |
| Q1 2025 | -6.1% | +12 points |
| Q4 2024 | 2.2% | +17 points |
ZETA has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
ZETA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $88.3M | +68% |
| Q2 2026 | $64.4M | +62% |
| Q1 2026 | $46.7M | +46% |
| Q4 2025 | $60.9M | +72% |
| Q3 2025 | $52.4M | +78% |
| Q2 2025 | $39.7M | +63% |
| Q1 2025 | $32.1M | +70% |
| Q4 2024 | $35.4M | +66% |
ZETA has the edge over OSCR on cash flow, with more consistent year-over-year improvement.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ZETA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.1% | +8M shares |
| 1 year | +19% | +42.2M shares |
| 3 years | +67% | +107M shares |
| 5 years | +417% | +213M shares |
| Available history | +712% | +232M shares |
ZETA has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over ZETA on leverage, with a lower net debt burden relative to earnings.
ZETA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.7x | Net Cash |
| Q2 2026 | -1.0x | Net Cash |
| Q1 2026 | -1.1x | Net Cash |
| Q4 2025 | -1.6x | Net Cash |
| Q3 2025 | -3.0x | Net Cash |
| Q2 2025 | -4.5x | Net Cash |
| Q1 2025 | -14.1x | Net Cash |
ZETA has more cash than debt.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ZETA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 70.3 | Overbought |
| Stochastic | 75.8 | Neutral |
ZETA's weekly RSI is 70 (overbought) and its Stochastic is 76 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ZETA PE vs Technology Sector
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
ZETA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $32.6 | 15% above |
| 20 week MA | $28.6 | 30% above |
| 50 week MA | $22.6 | 65% above |
| 100 week MA | $19.7 | 89% above |
| 200 week MA | $16.7 | 123% above |
ZETA is in an uptrend: it's above all five of its weekly moving averages, and 123% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ZETA on returns for 2026, with the stronger performance.
ZETA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $8.27 | $8.40 | +1.6% |
| 2022 | $8.40 | $8.21 | -2.3% |
| 2023 | $8.21 | $8.82 | +7.4% |
| 2024 | $8.82 | $17.7 | +100% |
| 2025 | $17.7 | $20.7 | +17% |
| 2026 YTD | $20.7 | $37.3 | +80% |
ZETA has finished higher in four of the last five years. It's up 80% so far in 2026.